https://www.arvinas.com/congress-presentatio/antitumor-and-immunomodulatory-activity-of-arv-6723-a-protac-hpk1-degrader-across-high-and-low-immunogenic-solid-tumors/ 2026-03-24T10:03:19+00:00 https://www.arvinas.com/congress-presentatio/phase-1-2-study-of-arv-806-a-protac-kras-g12d-degrader-in-kras-g12d-mutated-advanced-solid-tumors-including-pancreatic-cancer/ 2026-03-24T10:09:45+00:00 https://www.arvinas.com/congress-presentatio/circulating-tumor-dna-biomarker-analyses-of-a-phase-1-2-study-evaluating-vepdegestrant-a-protac-estrogen-receptor-degrader-in-er-her2-advanced-breast-cancer/ 2026-03-24T10:20:10+00:00 https://www.arvinas.com/congress-presentatio/real-world-prevalence-of-esr1-mutations-among-patients-with-er-her2-metastatic-breast-cancer-after-first-line-treatment-with-endocrine-therapy-and-or-a-cdk4-6-inhibitor/ 2026-03-24T10:27:46+00:00 https://www.arvinas.com/congress-presentatio/subgroup-analyses-of-veritac-2-a-phase-3-trial-of-vepdegestrant-a-protac-er-degrader-vs-fulvestrant-in-er-her2-advanced-breast-cancer/ 2026-03-24T10:36:50+00:00 https://www.arvinas.com/congress-presentatio/arv-393-a-protac-bcl6-degrader-combined-with-the-cd20xcd3-bispecific-glofitamab-in-a-preclinical-model-of-hgbcl/ 2026-03-24T10:57:48+00:00 https://www.arvinas.com/congress-presentatio/arv-102-a-protac-lrrk2-degrader-modulates-pathways-associated-with-parkinsons-disease-and-progressive-supranuclear-palsy-proteomic-analyses-of-csf-from-non-human-primates-and-healthy-volun/ 2026-03-24T11:05:16+00:00 https://www.arvinas.com/congress-presentatio/development-of-a-discrete-choice-experiment-survey-to-assess-patient-preferences-for-treatment-of-metastatic-breast-cancer/ 2026-03-24T11:12:43+00:00 https://www.arvinas.com/congress-presentatio/real-world-burden-of-illness-in-patients-with-er-her2-abc-receiving-second-line-treatment-interim-results-of-longitudinal-health-utility-data/ 2026-03-24T11:18:52+00:00 https://www.arvinas.com/congress-presentatio/preclinical-antitumor-activity-of-potent-and-orally-bioavailable-protac-hpk1-degraders-as-monotherapy-or-combined-with-an-anti-pd-1-antibody/ 2026-03-24T11:23:33+00:00 https://www.arvinas.com/congress-presentatio/tactive-n-phase-2-study-of-neoadjuvant-vepdegestrant-a-protac-estrogen-receptor-er-degrader-or-anastrozole-in-postmenopausal-er-human-epidermal-growth-factor-receptor-2-negative-localized-breast/ 2026-03-24T11:56:54+00:00 https://www.arvinas.com/congress-presentatio/oral-arv-027-induces-polyq-ar-degradation-and-improves-muscle-strength-and-endurance-in-a-murine-model-of-sbma/ 2026-03-24T12:07:38+00:00 https://www.arvinas.com/congress-presentatio/first-in-human-study-to-assess-the-safety-pharmacokinetics-and-pharmacodynamics-of-single-and-multiple-ascending-doses-of-arv-102-a-protac-lrrk2-degrader-in-healthy-participants/ 2026-03-24T12:13:45+00:00 https://www.arvinas.com/congress-presentatio/a-relative-bioavailability-study-of-vepdegestrant-tablets-in-healthy-adult-participants/ 2026-03-24T12:29:01+00:00 https://www.arvinas.com/congress-presentatio/arv-393-a-protac-bcl6-degrader-combined-with-biologics-or-small-molecule-inhibitors-induces-tumor-regressions-in-diffuse-large-b-cell-lymphoma-models/ 2026-03-24T12:40:10+00:00 https://www.arvinas.com/congress-presentatio/arv-393-a-protac-bcl6-degrader-in-preclinical-models-of-diffuse-large-b-cell-lymphoma-nodal-t-follicular-helper-cell-lymphoma-and-transformed-follicular-lymphoma/ 2026-03-24T12:42:49+00:00 https://www.arvinas.com/congress-presentatio/arv-393-a-proteolysis-targeting-chimera-protac-bcl6-degrader-combined-with-biologics-or-small-molecule-inhibitors-induces-tumor-regressions-in-diffuse-large-b-cell-lymphoma-models/ 2026-03-24T12:59:14+00:00 https://www.arvinas.com/congress-presentatio/arv-393-a-proteolysis-targeting-chimera-protac-bcl6-degrader-is-efficacious-in-preclinical-models-of-diffuse-large-b-cell-lymphoma-nodal-t-follicular-helper-cell-lymphoma-and-transformed-follicu/ 2026-03-24T13:04:01+00:00 https://www.arvinas.com/congress-presentatio/the-effect-of-carbamazepine-on-the-pharmacokinetics-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-in-healthy-adults/ 2026-03-24T13:14:43+00:00 https://www.arvinas.com/congress-presentatio/arv-393-a-proteolysis-targeting-chimera-protac-bcl6-degrader-combined-with-biologics-or-small-molecule-inhibitors-induces-tumor-regressions-in-diffuse-large-b-cell-lymphoma-models-2/ 2026-03-24T13:27:52+00:00 https://www.arvinas.com/congress-presentatio/first-in-human-study-to-assess-the-safety-pharmacokinetics-and-pharmacodynamics-of-arv-102-a-protac-lrrk2-degrader-in-healthy-volunteers-2/ 2026-03-24T13:47:58+00:00 https://www.arvinas.com/congress-presentatio/evaluation-of-the-combination-of-vepdegestrant-a-protac-estrogen-receptor-degrader-plus-palbociclib-in-cdk4-6-inhibitor-resistant-wild-type-and-estrogen-receptor-y537s-mutant-patient/ 2026-03-24T14:03:31+00:00 https://www.arvinas.com/congress-presentatio/population-pharmacokinetic-poppk-model-to-characterize-pharmacokinetics-pk-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-in-healthy-adult-participants/ 2026-03-24T14:08:20+00:00 https://www.arvinas.com/congress-presentatio/trial-in-progress-phase-1-study-of-arv-393-a-proteolysis-targeting-chimera-protac-b-cell-lymphoma-6-degrader-in-advanced-non-hodgkin-lymphoma/ 2026-03-24T14:14:24+00:00 https://www.arvinas.com/congress-presentatio/development-of-potent-orally-bioavailable-protac-lrrk2-degrader-molecules-as-potential-disease-modifying-therapeutics-for-neurodegeneration/ 2026-03-24T14:19:32+00:00 https://www.arvinas.com/congress-presentatio/oral-arv-393-is-a-bcl6-degrading-protac-efficacious-as-a-monotherapy-in-b-cell-lymphoma-preclinical-cdx-and-pdx-models/ 2026-03-25T06:23:53+00:00 https://www.arvinas.com/congress-presentatio/vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-plus-palbociclib-in-estrogen-receptor-human-epidermal-growth-factor-receptor-2-advanced-breast-cancer-updated-pha/ 2026-03-25T06:40:31+00:00 https://www.arvinas.com/congress-presentatio/tactive-k-phase-1b-2-study-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-in-combination-with-pf-07220060-a-cyclin-dependent-kinase-4-inhibitor-in-estrogen-r-2/ 2026-03-25T06:47:59+00:00 https://www.arvinas.com/congress-presentatio/arv-766-a-protac-androgen-receptor-degrader-combined-with-abiraterone-in-novel-hormonal-agent-naive-metastatic-prostate-cancer-phase-1-cohort-part-c-of-a-phase-1-2-study/ 2026-03-25T07:15:48+00:00 https://www.arvinas.com/congress-presentatio/the-discovery-of-arv-393-a-potent-orally-bioavailable-bcl6-targeting-protac-for-the-treatment-of-nhl/ 2026-03-25T07:30:43+00:00 https://www.arvinas.com/congress-presentatio/safety-and-pharmacokinetics-pk-of-vepdegestrant-in-japanese-patients-with-estrogen-receptor-er-human-epidermal-growth-factor-receptor-2-her2-advanced-breast-cancer-results-from-a-japanese-phas/ 2026-03-25T09:25:53+00:00 https://www.arvinas.com/congress-presentatio/global-phase-3-studies-evaluating-vepdegestrant-in-estrogen-receptor-er-human-epidermal-growth-factor-receptor-2-her2-advanced-breast-cancer-veritac-2-and-veritac-3/ 2026-03-25T09:31:54+00:00 https://www.arvinas.com/congress-presentatio/lrrk2-protac-degrader-molecules-induce-robust-biomarker-responses-in-preclinical-in-vivo-pharmacology-studies-following-acute-and-chronic-oral-dosing/ 2026-03-25T10:32:16+00:00 https://www.arvinas.com/congress-presentatio/tactive-u-phase-1b-2-umbrella-study-of-arv-471-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-combined-with-other-anticancer-treatments-in-er-advanced-or-metastatic-breas/ 2026-03-25T10:36:27+00:00 https://www.arvinas.com/congress-presentatio/veritac-2-a-global-randomized-phase-3-study-of-arv-471-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-vs-fulvestrant-in-er-human-epidermal-growth-factor-receptor-2-her2/ 2026-03-25T10:42:27+00:00 https://www.arvinas.com/congress-presentatio/the-arvinas-protac-discovery-engine-protac-biophysical-characterization-fuels-the-discovery-of-target-and-e3-ligase-ligands-for-optimized-protac-degrader-molecules/ 2026-03-25T10:46:24+00:00 https://www.arvinas.com/congress-presentatio/tactive-n-open-label-randomized-noncomparative-neoadjuvant-phase-2-study-of-arv-471-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-or-anastrozole-in-postmenopausal-women/ 2026-03-25T10:55:44+00:00 https://www.arvinas.com/congress-presentatio/veritac-update-phase-2-study-of-arv-471-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-in-er-human-epidermal-growth-factor-receptor-2-her2-advanced-breast-cancer/ 2026-03-25T10:58:46+00:00 https://www.arvinas.com/congress-presentatio/tactive-e-phase-1b-study-of-arv-471-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-in-combination-with-everolimus-in-er-human-epidermal-growth-factor-receptor-2-her2-ad/ 2026-03-25T11:01:52+00:00 https://www.arvinas.com/congress-presentatio/veritac-2-a-global-randomized-phase-3-study-of-arv-471-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-vs-fulvestrant-in-er-human-epidermal-growth-factor-receptor-2-her2-2/ 2026-03-25T11:04:30+00:00 https://www.arvinas.com/congress-presentatio/small-molecule-protac-hijacking-and-structural-characterization-of-an-e3-ligase-klhdc2-for-targeted-protein-degradation/ 2026-03-25T11:12:36+00:00 https://www.arvinas.com/congress-presentatio/kras-targeted-protac-degraders-are-broadly-efficacious-against-kras-dependent-tumor-models/ 2026-03-25T11:30:09+00:00 https://www.arvinas.com/congress-presentatio/a-phase-2-expansion-study-of-arv-766-a-protac-androgen-receptor-ar-degrader-in-metastatic-castration-resistant-prostate-cancer-mcrpc/ 2026-03-25T11:36:20+00:00 https://www.arvinas.com/congress-presentatio/real-world-outcomes-of-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-tumors-harboring-androgen-receptor-ar-ligand-binding-domain-lbd-mutations/ 2026-03-25T16:01:42+00:00 https://www.arvinas.com/congress-presentatio/first-clinical-trials-of-arv-102-a-protac-lrrk2-degrader-characterization-of-pathway-engagement-in-healthy-volunteers-and-patients-with-parkinsons-disease/ 2026-03-25T16:10:06+00:00 https://www.arvinas.com/congress-presentatio/development-of-potent-orally-bioavailable-and-highly-selective-lrrk2-protac-degrader-molecules-as-potential-disease-modifying-therapeutics-for-parkinsons-disease/ 2026-03-25T16:13:03+00:00 https://www.arvinas.com/congress-presentatio/leveraging-a-pharmacokinetic-pharmacodynamic-pk-pd-model-to-guide-dose-optimization-of-palbociclib-in-combination-with-vepdegestrant/ 2026-03-25T16:28:37+00:00 https://www.arvinas.com/congress-presentatio/tactive-k-phase-1b-2-study-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-in-combination-with-pf-07220060-a-cyclin-dependent-kinase-4-inhibitor-in-estrogen-r/ 2026-03-31T14:58:25+00:00 https://www.arvinas.com/congress-presentatio/arv-766-a-proteolysis-targeting-chimera-protac-androgen-receptor-degrader-in-metastatic-castration-resistant-prostate-cancer-initial-results-of-a-phase-1-2-study/ 2026-03-31T15:01:16+00:00 https://www.arvinas.com/congress-presentatio/vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-plus-palbociclib-in-estrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-adv/ 2026-03-31T15:19:22+00:00 https://www.arvinas.com/congress-presentatio/updated-results-from-veritac-evaluating-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-in-er-positive-human-epidermal-growth-factor-receptor-2-her2/ 2026-03-31T15:20:57+00:00 https://www.arvinas.com/congress-presentatio/tactive-u-phase-1b-2-umbrella-study-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-combined-with-other-anticancer-treatments-in-er-positive-advanced-or-me/ 2026-03-31T15:21:09+00:00 https://www.arvinas.com/congress-presentatio/veritac-2-a-phase-3-study-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-er-degrader-vs-fulvestrant-in-er-positive-human-epidermal-growth-factor-receptor-2-her2-neg/ 2026-03-31T15:22:11+00:00 https://www.arvinas.com/congress-presentatio/veritac-3-a-randomized-phase-3-study-with-a-lead-in-of-first-line-vepdegestrant-palbociclib-vs-letrozole-palbociclib-in-estrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-negat/ 2026-03-31T15:22:44+00:00 https://www.arvinas.com/congress-presentatio/drug-drug-interaction-study-of-the-proteolysis-targeting-chimera-protac-androgen-receptor-degrader-bavdegalutamide-in-combination-with-the-cyp3a4-inhibitor-itraconazole-in-healthy-volunteers/ 2026-03-31T15:29:23+00:00 https://www.arvinas.com/congress-presentatio/preclinical-activity-of-arv-806-a-protac-kras-g12d-degrader/ 2026-03-31T15:34:40+00:00 https://www.arvinas.com/congress-presentatio/the-effect-of-itraconazole-on-the-pharmacokinetics-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-in-healthy-adult-participants/ 2026-03-31T15:37:25+00:00 https://www.arvinas.com/congress-presentatio/the-effect-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-on-dabigatran-pharmacokinetics-in-healthy-adult-participants/ 2026-03-31T15:39:48+00:00 https://www.arvinas.com/congress-presentatio/evaluation-of-the-effect-of-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-on-rosuvastatin-pharmacokinetics-in-healthy-adult-participants/ 2026-03-31T15:40:40+00:00 https://www.arvinas.com/congress-presentatio/drug-drug-interaction-study-of-the-proteolysis-targeting-chimera-protac-androgen-receptor-degrader-bavdegalutamide-in-combination-with-the-p-glycoprotein-substrate-fexofenadine-in-healthy-male-volun/ 2026-03-31T15:42:27+00:00 https://www.arvinas.com/congress-presentatio/vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-in-estrogen-receptor-human-epidermal-growth-factor-receptor-2-advanced-breast-cancer-update-of-dose-escalation-res/ 2026-03-31T15:45:27+00:00 https://www.arvinas.com/congress-presentatio/phase-1-2-study-of-bavdegalutamide-a-proteolysis-targeting-chimera-protac-androgen-receptor-degrader-in-metastatic-castration-resistant-prostate-cancer-radiographic-progression-free-survival-in-p/ 2026-03-31T15:47:48+00:00 https://www.arvinas.com/congress-presentatio/preclinical-activity-of-an-orally-bioavailable-protac-pan-kras-degrader-versus-inhibitors-in-mutant-kras-models-2/ 2026-03-31T15:49:38+00:00 https://www.arvinas.com/congress-presentatio/preclinical-activity-of-an-orally-bioavailable-protac-pan-kras-degrader-versus-inhibitors-in-mutant-kras-models/ 2026-03-31T15:49:42+00:00 https://www.arvinas.com/congress-presentatio/mechanisms-of-acquired-resistance-to-arv-471-a-novel-protac-estrogen-receptor-degrader/ 2026-03-31T15:54:46+00:00 https://www.arvinas.com/congress-presentatio/enhanced-efficacy-of-arv-471-a-novel-protac-estrogen-receptor-degrader-in-combination-with-targeted-agents-in-estrogen-receptor-positive-er-breast-cancer-models/ 2026-03-31T15:55:50+00:00 https://www.arvinas.com/congress-presentatio/absorption-metabolism-excretion-and-pharmacokinetics-of-14c-vepdegestrant-in-healthy-adult-participants/ 2026-03-31T15:57:48+00:00 https://www.arvinas.com/congress-presentatio/phase-1-study-of-arv-393-a-protac-bcl6-degrader-in-advanced-non-hodgkin-lymphoma/ 2026-03-31T15:59:30+00:00 https://www.arvinas.com/congress-presentatio/vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-plus-abemaciclib-in-estrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-adv/ 2026-03-31T16:02:08+00:00 https://www.arvinas.com/congress-presentatio/evaluating-cyp3a4-mediated-drug-interaction-risks-for-vepdegestrant-a-proteolysis-targeting-chimera-protac-estrogen-receptor-degrader-in-combination-with-cyclin-dependent-kinase-4-6-inhibitors-and/ 2026-03-31T16:02:22+00:00 https://www.arvinas.com/congress-presentatio/first-in-human-study-to-assess-the-safety-pharmacokinetics-and-pharmacodynamics-of-arv-102-a-protac-lrrk2-degrader-in-healthy-volunteers/ 2026-03-31T16:06:27+00:00 https://www.arvinas.com/congress-presentatio/the-effect-of-food-and-the-proton-pump-inhibitor-esomeprazole-on-the-single-dose-pharmacokinetics-and-safety-of-the-proteolysis-targeting-chimera-protac-androgen-receptor-degrader-bavdegalutamide-in/ 2026-03-31T16:10:48+00:00 https://www.arvinas.com/congress-presentatio/the-effect-of-food-and-the-proton-pump-inhibitor-esomeprazole-on-the-single-dose-pharmacokinetics-and-safety-of-arv-766-a-proteolysis-targeting-chimera-protac-androgen-receptor-degrader-in-healthy/ 2026-03-31T16:12:37+00:00 https://www.arvinas.com/congress-presentatio/vepdegestrant-a-protac-er-degrader-induces-greater-er-degradation-and-antitumor-activity-relative-to-serds-in-preclinical-er-breast-cancer-models/ 2026-03-31T16:38:42+00:00 https://www.arvinas.com/congress-presentatio/in-vitro-evaluation-of-protac-androgen-receptor-degrader-arv-766-for-cytochrome-p450-and-transporter-mediated-drug-drug-interaction/ 2026-04-08T03:09:08+00:00 https://www.arvinas.com/congress-presentatio/discovery-of-arv-766-an-androgen-receptor-degrading-protac-for-the-treatment-of-men-with-metastatic-castration-resistant-prostate-cancer/ 2026-04-08T03:10:25+00:00 https://www.arvinas.com/congress-presentatio/safety-pharmacokinetics-and-pharmacodynamics-of-multiple-doses-of-arv-102-a-protac-lrrk2-degrader-in-participants-with-parkinsons-disease/ 2026-04-13T09:35:59+00:00 https://www.arvinas.com/congress-presentatio/preclinical-antitumor-and-immunomodulatory-activity-of-arv-6723-a-protac-hpk1-degrader-versus-icis/ 2026-04-21T15:54:30+00:00 https://www.arvinas.com/congress-presentatio/preclinical-efficacy-of-a-protac-pan-kras-degrader-in-a-kras-g12d-syngeneic-mouse-model-and-concurrent-immune-tme-changes/ 2026-04-21T15:55:04+00:00 https://www.arvinas.com/congress-presentatio/phase-1-study-of-arv-393-a-protac-bcl6-degrader-as-monotherapy-in-patients-with-advanced-nhl-or-combined-with-glofitamab-in-patients-with-dlbc/ 2026-06-03T14:11:06+00:00 https://www.arvinas.com/congress-presentatio/phase-1-study-of-arv-393-a-protac-bcl6-degrader-as-monotherapy-in-patients-with-advanced-nhl-or-combined-with-glofitamab-in-patients-with-dlbcl/ 2026-06-03T14:11:43+00:00 https://www.arvinas.com/congress-presentatio/arv-393-a-protac-bcl6-degrader-combined-with-the-cd20xcd3-bispecific-glofitamab-in-a-preclinical-model-of-hgbcl-2/ 2026-06-03T18:00:06+00:00 https://www.arvinas.com/congress-presentatio/patient-reported-outcomes-pros-with-vepdegestrant-vep-vs-fulvestrant-ful-in-patients-pts-with-estrogen-receptor-er-1-gene-mutated-esr1m-er-human-epidermal-growth-factor-receptor-2-her2/ 2026-06-12T07:09:08+00:00 https://www.arvinas.com/congress-presentatio/vepdegestrant-a-protac-estrogen-receptor-er-degrader-vs-fulvestrant-in-er-positive-human-epidermal-growth-factor-receptor-2-her2-negative-advanced-breast-cancer-results-of-the-global-r/ 2026-06-12T07:12:58+00:00 https://www.arvinas.com/congress-presentatio/protac-lrrk2-degraders-reduce-pathological-tau-and-modulate-endolysosomal-neuroinflammatory-pathways-in-translational-model-systems/ 2026-07-13T14:37:23+00:00